Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up
Table 7
Univariate regression logistic analysis of the risk of cardiovascular mortality.
Group of factors
Factor
AF-HFpEF
AF-HFmrEF
AF-HFrEF
OR (2.5–97.5)
value
OR (2.5–97.5)
value
OR (2.5–97.5)
value
Laboratory tests
Total cholesterol
0.515 (0.291–0.851)
0.014
International normalised ratio
2.825 (1.353–7.937)
0.013
NT-proBNР
1.001 (1–1.002)
0.055
Habits and lifestyle
Balanced diet
0.355 (0.102–1.279)
0.099
Symptoms and syndromes
Anemia
5.618 (1.799–16.667)
0.002
4.219 (1.156–14.286)
0.022
The number of specific signs of HF (pressure in the jugular veins, gallop rhythm, mixing the top of the jolt, wheezing in the lungs, and congestion in the lungs)
2.299 (1.441–3.676)
<0.001
1.567 (0.924–2.653)
0.089
1.497 (1.163–1.927)
0.002
The number of typical symptoms of HF (dyspnea, fatigue, orthopnea, low effort tolerance, fatigue, edema, and apnoea)
1.961 (1.335–2.941)
0.001
1.346 (1.121–1.629)
0.002
Concomitant diseases
Endoscopy presence of erosive ulcerative lesions gastrointestinal mucosa
2.353 (0.951–5.464)
0.053
Abnormal liver function
5.291 (1.425–18.519)
0.009
Renal disease
4.184 (1.245–12.5)
0.013
CV system characteristics
Aortic valve insufficiency
2.907 (0.915–10.101)
0.075
Arterial hypertension
2 (1.089–3.891)
0.032
The duration of arterial hypertension (years)
1.066 (1.017–1.116)
0.006
Cardiothoracic index (%)
1.597 (1.133–2.841)
0.036
1.161 (1.053–1.294)
0.004
History of infarction and/or stroke
3.521 (1.222–11.494)
0.024
Degree of pulmonary insufficiency
2.725 (1.269–5.882)
0.009
Right atrium enlargement
3.546 (1.235–14.925)
0.04
Degree of tricuspid insufficiency
1.37 (0.983–1.908)
0.061
Echocardiographic signs of myocardial infarct (cicatricial changes and local conduction disturbance zones)
3.636 (1.233–10.526)
0.016
1.957 (1.129–3.509)
0.02
Enlarged pulmonary trunk
2.375 (1.224–4.608)
0.01
Prior major bleeding
6.494 (2.174–19.231)
0.001
3.891 (1.073–13.158)
0.03
Therapy
Regular use of anticoagulants
0.389 (0.225–0.666)
0.001
Regular use of NOAC
0.42 (0.202–0.806)
0.013
Regular use of peripheral vasodilators
4.587 (1.695–11.905)
0.002
Regular use of statins
0.254 (0.083–0.724)
0.011
0.627 (0.366–1.08)
0.089
Regular use of ACE inhibitors
0.22 (0.069–0.84)
0.015
Permanent AF therapy with beta-blockers
0.404 (0.213–0.791)
0.006
Permanent AF therapy with calcium channel blockers
